Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

KEDRION-IPIC-2025

More Like This

PR Newswire associated0

Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity

PR Newswire associated0

European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

PR Newswire associated0

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023